TrialCancer medicine2013

A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial.

Siow Ming Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.